India bans export of Remdesivir |
India has prohibited exports of injection Remdesivir and its Active Pharmaceutical Ingredients (APIs) till the COVID situation in the country improves. The Union Health Ministry has said that India is witnessing a recent surge in COVID cases and there are over 1.1 million active COVID cases. This has led to a sudden spike in demand for injection Remdesivir used in the treatment of COVID patients. The Ministry added that there is a huge scope for its growing demand in the coming days. The Ministry said all domestic manufactures of Remdesivir have been advised to display on their website, details of their stockists and distributors to facilitate access to the drug. It said that drug inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb its hoarding and black marketing. The State Health Secretaries will review this with the Drug Inspectors of the respective States and Union Territories. The Ministry said the Department of Pharmaceuticals has been in contact with the domestic manufacturers to ramp up the production of Remdesivir. Seven Indian companies are producing injection Remdesivir under a voluntary licensing agreement with Gilead Sciences, USA. They have an installed capacity of about 3.88 million units per month. Meanwhile, the state of Maharashtra reported the highest single-day jump in Covid-19 cases, breaching the 60,000-mark on 11th April. The state reported 63,294 cases, taking the total tally to 3 million 407 thousand 245. With 349 more deaths, the death toll has risen to 57,987. Mumbai reported nearly 10 thousand cases. According to the Brihanmumbai Municipal Corporation (BMC) 9,989 fresh cases of Covid were reported and 58 patients succumbed in the last 24 hours.
|
|
|
|